Formulation Development for an ADC: Solution Vs. Lyophilization - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Formulation Development for an ADC: Solution Vs. Lyophilization

3:30 pm - Tuesday 13th October 2026

Evaluating short-term, accelerated solution stability to identify the best formulation candidates
Evaluating interfacial interactions to determine the need for a surfactant
Utilizing statistical design of experiments to compare formulation components
Comparing formulations using stability indicating methods

Speakers:

Gregory Sacha

Gregory Sacha

Senior Scientist

Simtra BioPharma Solutions